CA3096890A1 - Gabaa positive allosteric modulator compounds, methods of making, and uses thereof - Google Patents
Gabaa positive allosteric modulator compounds, methods of making, and uses thereof Download PDFInfo
- Publication number
- CA3096890A1 CA3096890A1 CA3096890A CA3096890A CA3096890A1 CA 3096890 A1 CA3096890 A1 CA 3096890A1 CA 3096890 A CA3096890 A CA 3096890A CA 3096890 A CA3096890 A CA 3096890A CA 3096890 A1 CA3096890 A1 CA 3096890A1
- Authority
- CA
- Canada
- Prior art keywords
- crystal
- crystalline salt
- crystalline
- pattern
- phosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862659226P | 2018-04-18 | 2018-04-18 | |
| US62/659,226 | 2018-04-18 | ||
| PCT/US2019/027880 WO2019204446A1 (en) | 2018-04-18 | 2019-04-17 | Gabaa positive allosteric modulator compounds, methods of making, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3096890A1 true CA3096890A1 (en) | 2019-10-24 |
Family
ID=68239798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3096890A Pending CA3096890A1 (en) | 2018-04-18 | 2019-04-17 | Gabaa positive allosteric modulator compounds, methods of making, and uses thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11542263B2 (enExample) |
| EP (1) | EP3781566A4 (enExample) |
| JP (3) | JP7449272B2 (enExample) |
| KR (2) | KR20250057112A (enExample) |
| CN (2) | CN121135719A (enExample) |
| AU (2) | AU2019255282B2 (enExample) |
| BR (1) | BR112020021104A2 (enExample) |
| CA (1) | CA3096890A1 (enExample) |
| CL (1) | CL2020002663A1 (enExample) |
| IL (1) | IL278067A (enExample) |
| MX (2) | MX2020010878A (enExample) |
| SG (1) | SG11202010220QA (enExample) |
| TW (1) | TW202012402A (enExample) |
| WO (1) | WO2019204446A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020021104A2 (pt) * | 2018-04-18 | 2021-02-23 | Neurocycle Therapeutics, Inc | compostos moduladores alostéricos positivos gabaa, métodos de produção e usos dos mesmos |
| CA3132810A1 (en) * | 2019-03-18 | 2020-09-24 | Neurocycle Therapeutics, Inc. | Use of gabaa receptor modulators for treatment of fybromyalgia |
| JP2022553718A (ja) * | 2019-10-22 | 2022-12-26 | ニューロサイクル・セラピューティクス・インコーポレイテッド | Ｇａｂａａ陽性アロステリック調節因子化合物、作成方法、およびその使用 |
| CN120267677A (zh) * | 2019-10-23 | 2025-07-08 | 纽罗塞克医疗公司 | 用gabaa受体调节剂的癫痫状况的治疗 |
| US12233070B2 (en) * | 2020-06-30 | 2025-02-25 | University Of Mississippi Medical Center | Methods for treating benzodiazepine misuse/use disorder |
| JP2025535716A (ja) * | 2022-10-04 | 2025-10-28 | エングレイル セラピューティクス，インコーポレーテッド | Ｇａｂａａ受容体モジュレーターおよびその使用 |
| WO2025175214A1 (en) * | 2024-02-16 | 2025-08-21 | Engrail Therapeutics, Inc. | Methods of treating generalized anxiety disorder |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2802343C2 (de) | 1978-01-20 | 1982-04-22 | Peter Prof. Dr.-Ing. Friderichs | Latentwärmespeicher-Behälter |
| GB9813576D0 (en) * | 1998-06-24 | 1998-08-19 | Merck Sharp & Dohme | Therapeutic agents |
| GB0117277D0 (en) * | 2001-07-16 | 2001-09-05 | Merck Sharp & Dohme | Therapeutic agents |
| CA2427779A1 (en) * | 2000-11-10 | 2002-05-16 | Merck Sharp & Dohme Limited | Imidazo-triazine derivatives as ligands for gaba receptors |
| TWI248936B (en) * | 2001-03-21 | 2006-02-11 | Merck Sharp & Dohme | Imidazo-pyrimidine derivatives as ligands for GABA receptors |
| JP2004170323A (ja) | 2002-11-22 | 2004-06-17 | Sumitomo Pharmaceut Co Ltd | 皮膚疾患治療剤のスクリーニング方法 |
| WO2009021957A2 (en) | 2007-08-14 | 2009-02-19 | Novartis Ag | Tricyclic heterocyclic compounds as gaba a modulators |
| TWI472529B (zh) * | 2008-05-21 | 2015-02-11 | Incyte Corp | ２－氟－Ｎ－甲基－４－〔７－（喹啉－６－基－甲基）－咪唑并〔１，２－ｂ〕〔１，２，４〕三－２－基〕苯甲醯胺之鹽類及其相關製備方法 |
| WO2011011712A1 (en) * | 2009-07-24 | 2011-01-27 | Concert Pharmaceuticals, Inc. | Substituted imidazotriazines |
| AU2014219855B2 (en) | 2013-02-19 | 2017-09-28 | Ono Pharmaceutical Co., Ltd. | Trk-inhibiting compound |
| WO2015072853A1 (en) | 2013-11-13 | 2015-05-21 | Rjg Developments B.V. | Treatment of herpes virus infection outbreaks |
| WO2017129801A1 (en) * | 2016-01-27 | 2017-08-03 | Universität Zürich | Use of gabaa receptor modulators for treatment of itch |
| BR112020021104A2 (pt) * | 2018-04-18 | 2021-02-23 | Neurocycle Therapeutics, Inc | compostos moduladores alostéricos positivos gabaa, métodos de produção e usos dos mesmos |
-
2019
- 2019-04-17 BR BR112020021104-4A patent/BR112020021104A2/pt unknown
- 2019-04-17 CA CA3096890A patent/CA3096890A1/en active Pending
- 2019-04-17 EP EP19788410.9A patent/EP3781566A4/en active Pending
- 2019-04-17 WO PCT/US2019/027880 patent/WO2019204446A1/en not_active Ceased
- 2019-04-17 CN CN202511219750.2A patent/CN121135719A/zh active Pending
- 2019-04-17 TW TW108113441A patent/TW202012402A/zh unknown
- 2019-04-17 SG SG11202010220QA patent/SG11202010220QA/en unknown
- 2019-04-17 CN CN201980041321.7A patent/CN112384513A/zh active Pending
- 2019-04-17 JP JP2021506619A patent/JP7449272B2/ja active Active
- 2019-04-17 AU AU2019255282A patent/AU2019255282B2/en active Active
- 2019-04-17 MX MX2020010878A patent/MX2020010878A/es unknown
- 2019-04-17 KR KR1020257012376A patent/KR20250057112A/ko active Pending
- 2019-04-17 KR KR1020207033073A patent/KR102799156B1/ko active Active
-
2020
- 2020-10-14 MX MX2024004400A patent/MX2024004400A/es unknown
- 2020-10-15 CL CL2020002663A patent/CL2020002663A1/es unknown
- 2020-10-15 IL IL278067A patent/IL278067A/en unknown
- 2020-10-16 US US17/072,282 patent/US11542263B2/en active Active
-
2022
- 2022-12-28 US US18/089,661 patent/US12134619B2/en active Active
-
2024
- 2024-02-29 JP JP2024030150A patent/JP7721712B2/ja active Active
- 2024-10-02 US US18/904,228 patent/US20250034155A1/en active Pending
- 2024-11-07 AU AU2024259803A patent/AU2024259803A1/en active Pending
-
2025
- 2025-07-30 JP JP2025127411A patent/JP2025166011A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020021104A2 (pt) | 2021-02-23 |
| WO2019204446A1 (en) | 2019-10-24 |
| AU2024259803A1 (en) | 2024-11-28 |
| MX2020010878A (es) | 2021-01-29 |
| JP7449272B2 (ja) | 2024-03-13 |
| JP2025166011A (ja) | 2025-11-05 |
| AU2019255282B2 (en) | 2024-08-08 |
| CN112384513A (zh) | 2021-02-19 |
| KR102799156B1 (ko) | 2025-04-21 |
| KR20250057112A (ko) | 2025-04-28 |
| US11542263B2 (en) | 2023-01-03 |
| US20230139418A1 (en) | 2023-05-04 |
| JP2021522330A (ja) | 2021-08-30 |
| EP3781566A4 (en) | 2022-06-22 |
| CL2020002663A1 (es) | 2021-06-11 |
| IL278067A (en) | 2020-11-30 |
| AU2019255282A1 (en) | 2020-11-05 |
| SG11202010220QA (en) | 2020-11-27 |
| JP2024063136A (ja) | 2024-05-10 |
| US20210040103A1 (en) | 2021-02-11 |
| JP7721712B2 (ja) | 2025-08-12 |
| US20250034155A1 (en) | 2025-01-30 |
| EP3781566A1 (en) | 2021-02-24 |
| MX2024004400A (es) | 2024-04-29 |
| TW202012402A (zh) | 2020-04-01 |
| CN121135719A (zh) | 2025-12-16 |
| US12134619B2 (en) | 2024-11-05 |
| KR20210011921A (ko) | 2021-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12134619B2 (en) | Crystalline salts or co-crystals of 2′,6-difluoro-5′-[3-(1-hydroxy-1-methylethyl)-imidazo[1,2-b][1,2,4]triazin-7-yl]biphenyl-2-carbonitrile with p-toluenesulofonic acid as GABAA positive allosteric modulators | |
| CA2852771C (en) | Process for preparing quinoline derivatives | |
| KR102442536B1 (ko) | 리나글립틴 결정형 및 이의 제조방법 | |
| JP2017002048A (ja) | ピリミド［６，１−ａ］イソキノリン−４−オン化合物の結晶形態 | |
| JP2008534656A (ja) | アセナピン・マレイン酸塩の結晶形 | |
| US12319652B2 (en) | Salts and solid forms of (R)-1-(5-methoxy-1H-indol-1-yl)-N,N-dimethylpropan-2-amine | |
| CA3146130A1 (en) | Formulations of rbp4 inhibitors and methods of use | |
| JP2026021408A (ja) | Ｇａｂａａ陽性アロステリック調節因子化合物、作成方法、およびその使用 | |
| US12617794B2 (en) | GABAA positive allosteric modulator compounds, methods of making, and uses thereof | |
| JP2020073523A (ja) | 置換されたイミダゾピリジニル−アミノピリジン化合物の塩および多型 | |
| KR20250043448A (ko) | 신규 염 및 결정 | |
| WO2019109802A1 (zh) | 一种取代的硼酸酯化合物的制备方法及其晶型 | |
| WO2022048620A1 (en) | Polymorphs of crystalline forms of 3, 10-dimethoxy-5, 8, 13, 13a-tetrahydro-6h-isoquinolino [3, 2-a] isoquinolin-9-yl 3-fluorobenzenesulfonate and salts thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220930 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20240808 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241231 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250324 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250401 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250401 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250414 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250414 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250714 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250808 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251114 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260112 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260112 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260112 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260415 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260415 |